MTM Investment Management LLC Buys 1,200 Shares of Elanco Animal Health Incorporated (NYSE:ELAN)

MTM Investment Management LLC grew its stake in Elanco Animal Health Incorporated (NYSE:ELAN) by 9.3% in the 4th quarter, Holdings Channel.com reports. The fund owned 14,168 shares of the company’s stock after purchasing an additional 1,200 shares during the quarter. MTM Investment Management LLC’s holdings in Elanco Animal Health were worth $172,000 as of its most recent SEC filing.

Several other hedge funds also recently modified their holdings of ELAN. Van ECK Associates Corp lifted its stake in Elanco Animal Health by 4.0% in the 4th quarter. Van ECK Associates Corp now owns 944,978 shares of the company’s stock valued at $11,444,000 after purchasing an additional 36,239 shares during the last quarter. Summit Trail Advisors LLC acquired a new stake in Elanco Animal Health in the 4th quarter valued at about $199,000. Equitable Trust Co. acquired a new stake in Elanco Animal Health in the 4th quarter valued at about $1,524,000. Empowered Funds LLC acquired a new stake in Elanco Animal Health in the 4th quarter valued at about $142,000. Finally, Hedeker Wealth LLC lifted its stake in Elanco Animal Health by 3.5% in the 4th quarter. Hedeker Wealth LLC now owns 133,776 shares of the company’s stock valued at $1,620,000 after purchasing an additional 4,512 shares during the last quarter. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Stock Down 0.3 %

NYSE ELAN opened at $11.38 on Thursday. The business has a fifty day moving average price of $11.97 and a two-hundred day moving average price of $13.17. The company has a debt-to-equity ratio of 0.66, a current ratio of 2.55 and a quick ratio of 1.31. Elanco Animal Health Incorporated has a fifty-two week low of $11.11 and a fifty-two week high of $18.80. The stock has a market capitalization of $5.63 billion, a PE ratio of 28.45, a PEG ratio of 2.69 and a beta of 1.42.

Analyst Ratings Changes

ELAN has been the subject of several recent analyst reports. Barclays raised their target price on shares of Elanco Animal Health from $19.00 to $20.00 and gave the company an “overweight” rating in a research note on Friday, November 8th. Leerink Partnrs upgraded shares of Elanco Animal Health to a “hold” rating in a research note on Monday, December 2nd. Stifel Nicolaus cut their price objective on shares of Elanco Animal Health from $20.00 to $18.00 and set a “buy” rating for the company in a research report on Tuesday, January 7th. Leerink Partners began coverage on shares of Elanco Animal Health in a research report on Monday, December 2nd. They set a “market perform” rating and a $14.00 price objective for the company. Finally, UBS Group assumed coverage on shares of Elanco Animal Health in a research report on Monday, December 9th. They set a “buy” rating and a $18.00 price objective for the company. One research analyst has rated the stock with a sell rating, four have given a hold rating and three have assigned a buy rating to the company’s stock. According to MarketBeat, the stock presently has an average rating of “Hold” and a consensus target price of $16.29.

Elanco Animal Health Profile

Elanco Animal Health Incorporated, an animal health company, innovates, develops, manufactures, and markets products for pets and farm animals. It offers pet health disease prevention products, such as parasiticide and vaccine products that protect pets from worms, fleas, and ticks under the Seresto, Advantage, Advantix, and Advocate brands; pet health therapeutics for pain, osteoarthritis, ear infections, cardiovascular, and dermatology indications in canines and felines under the Galliprant and Claro brands; vaccines, antibiotics, parasiticides, and other products for use in poultry and aquaculture production, as well as nutritional health products, including enzymes, probiotics, and prebiotics; and a range of vaccines, antibiotics, implants, parasiticides, and other products used in ruminant and swine production under the Rumensin and Baytril brands.